glp 1 pet scan GLP-1 agonists may interfere with cancer imaging, new study finds Glucagon-like Peptide-1 Receptor as Emerging

As of 2022, GLP-1RAs have been recommended as first-line treatments, along with SGLT-2 inhibitors, for patients with T2DM and cardiovascular disease in American Diabetes Associations Standards of Medical Care in Diabetes (248, 249)

Case report: amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide

A little patience here goes a long way

Who Should Avoid GLP-1s These medications are powerful, but not for everyone

In the SELECT trial, once weekly 2.4mg semaglutide led to a 20% reduction in MACE in non-diabetic, obese/overweight patients with established ASCVD

Aston-Mourney K, Subramanian SL, Zraika S, Samarasekera T, Meier DT, Goldstein LC, and Hull RL